Prior data suggest that baseline circulating plasma AFP and TGF‐β1, AFP and TGF‐β1 response kinetics, and tumor SMAD complex activity might discriminate a sensitive HCC subset.30 The gene discussed is TGFB1; the disease is hepatocellular carcinoma.